The US HAEA publishes any clinical trial information provided to us by our pharmaceutical sponsors immediately upon receipt.
Current clinical trials include:
A Phase III clinical trial to access the efficacy of subcutaneous liquid formulation of C1 esterase inhibitor for the prevention of angioedema attacks in adolescent and adult subjects with hereditary angioedema type I and II. The study is sponsored by Shire.
A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of subcutaneously administered DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE. This study is sponsored by Shire.
If you are interested in participating in this clinical trial, or would just like more information about other treatments under development, please contact US HAEA’s John Williamson, (972) 984-0621.
Please return to this page often to check for updates. And contact any of the HAEA Patient Advocates to learn about the five FDA-approved HAE therapies that can revolutionize HAE patients’ lives.